Артериальная гипертония и хроническая обструктивная болезнь легких: клиническая характеристика и эффективность лечения (по данным Национального регистра артериальной гипертонии) - Журнал Терапевтический архив №3 Вопросы пульмонологии 2019
Артериальная гипертония и хроническая обструктивная болезнь легких: клиническая характеристика и эффективность лечения (по данным Национального регистра артериальной гипертонии)
Чазова И.Е., Лазарева Н.В., Ощепкова Е.В. Артериальная гипертония и хроническая обструктивная болезнь легких: клиническая характеристика и эффективность лечения (по данным Национального регистра артериальной гипертонии). Терапевтический архив. 2019; 91 (3): #–10. DOI: 10.26442/00403660.2019.03.000110
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Артериальная гипертония (АГ) является одним из ведущих факторов, определяющих высокую смертность населения во многих странах мира, включая Россию. Естественное постарение населения начала ХХ века ведет за собой медицинские и социально-экономические проблемы, одной из которых является частая коморбидность. Распространенность хронической обструктивной болезни легких (ХОБЛ) среди населения, особенно у городских жителей и мужчин, достаточно велика. АГ и ХОБЛ – одно из частых коморбидных состояний, сочетание этих заболеваний определяет высокий уровень инвалидности и неблагоприятный прогноз.
Целью данного исследования явилось изучение демографической, клинической характеристики и эффективности лечения больных АГ с ХОБЛ на основе Национального регистра артериальной гипертонии.
Материалы и методы. Среди анализируемой выборки, состоявшей из 32 571 больного АГ, наблюдавшегося в первичном звене здравоохранения, среднего возраста 64±7 лет, из которых 64% составляли женщины, ХОБЛ выявлена у 5,4% больных АГ. Проводился анализ частоты сердечно-сосудистых и цереброваскулярных заболеваний и эффективности лечения у больных АГ с ХОБЛ.
Результаты. У больных АГ с ХОБЛ, по данным Национального регистра артериальной гипертонии, достоверно чаще диагностированы сердечно-сосудистые [ишемическая болезнь сердца, Q инфаркт миокарда, хроническая сердечная недостаточность (ХСН), атеросклероз периферических артерий] и цереброваскулярные заболевания (инсульт/транзиторная ишемическая атака).
Заключение. Независимым наиболее сильным фактором, определяющим риск развития сердечно-сосудистых заболеваний у этих больных, является мужской пол и возрастной фактор. ХОБЛ значительно повышает риск развития ХСН. Проведенный анализ показал, что лечение, назначенное больным АГ с ХОБЛ, соответствует современным рекомендациям.
Ключевые слова: артериальная гипертония, регистр артериальной гипертонии, диагностика, эффективность лечения.
The objective of the research is studying of demographic and clinical profile as well as treatment effectiveness of patients with AH and COPD based on National Register of Arterial Hypertension.
Methods and materials. Among the analyzed selection, consisted of 32 571 patients with AH, who were followed up in the primary medical care, at the average age of 64±7 years old (there were 64% women of them), 5.4% patients with AH had COPD. The analysis of cardiovascular and cerebrovascular diseases frequency as well as treatment effectiveness was made.
Results. According to National Register of Arterial Hypertension, cardiovascular [coronary heart disease, Q myocardial infarction, chronic heart failure (CHF), peripheral artery atherosclerosis] and cerebrovascular (stroke/transitory ischemic attack) diseases are accurately more often diagnosed at patients with AH and COPD.
Conclusion. Male sex and age are the strongest independent factor, contributing into the risk of development of cardiovascular diseases at these patients. COPD considerably increases the risk of CHF development. The conducted analysis has shown that treatment, prescribed to patients with AH and COPD meets modern recommendations.
Keywords: arterial hypertension, national register of arterial hypertension, diagnosis, treatment effectiveness.
Целью данного исследования явилось изучение демографической, клинической характеристики и эффективности лечения больных АГ с ХОБЛ на основе Национального регистра артериальной гипертонии.
Материалы и методы. Среди анализируемой выборки, состоявшей из 32 571 больного АГ, наблюдавшегося в первичном звене здравоохранения, среднего возраста 64±7 лет, из которых 64% составляли женщины, ХОБЛ выявлена у 5,4% больных АГ. Проводился анализ частоты сердечно-сосудистых и цереброваскулярных заболеваний и эффективности лечения у больных АГ с ХОБЛ.
Результаты. У больных АГ с ХОБЛ, по данным Национального регистра артериальной гипертонии, достоверно чаще диагностированы сердечно-сосудистые [ишемическая болезнь сердца, Q инфаркт миокарда, хроническая сердечная недостаточность (ХСН), атеросклероз периферических артерий] и цереброваскулярные заболевания (инсульт/транзиторная ишемическая атака).
Заключение. Независимым наиболее сильным фактором, определяющим риск развития сердечно-сосудистых заболеваний у этих больных, является мужской пол и возрастной фактор. ХОБЛ значительно повышает риск развития ХСН. Проведенный анализ показал, что лечение, назначенное больным АГ с ХОБЛ, соответствует современным рекомендациям.
Ключевые слова: артериальная гипертония, регистр артериальной гипертонии, диагностика, эффективность лечения.
________________________________________________
The objective of the research is studying of demographic and clinical profile as well as treatment effectiveness of patients with AH and COPD based on National Register of Arterial Hypertension.
Methods and materials. Among the analyzed selection, consisted of 32 571 patients with AH, who were followed up in the primary medical care, at the average age of 64±7 years old (there were 64% women of them), 5.4% patients with AH had COPD. The analysis of cardiovascular and cerebrovascular diseases frequency as well as treatment effectiveness was made.
Results. According to National Register of Arterial Hypertension, cardiovascular [coronary heart disease, Q myocardial infarction, chronic heart failure (CHF), peripheral artery atherosclerosis] and cerebrovascular (stroke/transitory ischemic attack) diseases are accurately more often diagnosed at patients with AH and COPD.
Conclusion. Male sex and age are the strongest independent factor, contributing into the risk of development of cardiovascular diseases at these patients. COPD considerably increases the risk of CHF development. The conducted analysis has shown that treatment, prescribed to patients with AH and COPD meets modern recommendations.
Keywords: arterial hypertension, national register of arterial hypertension, diagnosis, treatment effectiveness.
Список литературы
1. Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014;10:4-12 [Chazova IE, Zhernakova IuV, Oshchepkova EV i dr. Rasprostranennost' FR serdechno-sosudistykhzabolevanii v rossiiskoi populiatsii bol'nykh arterial'noi gipertoniei. Kardiologiia. 2014;10:4-12 (In Russ.)]. https://doi.org/10.26442/terarkh20189098-14
2. Чазова И.Е., Ощепкова Е.В. Итоги реализации Федеральной целевой программы по профилактике и лечению артериальной гипертензии в России в 2002–2012 гг. Вестник Российской академии медицинских наук. 2013;2:4-11 [Chazova IE, Oshchepkova EV. Itogi realizatsii Federal'noi tselevoi programmy po profilaktike i lecheniiu arterial'noi gipertenzii v Rossii v 2002–2012 gg. Vestn. Rossiiskoi Akademii meditsinskikh nauk. 2013;2:4-11 (In Russ.)].
3. Heart disease and Stroke statistics – 2016 update: a report from the American Heart Association. Circulation. 2016;133.
4. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA. 2003;289:2363-9. doi:10.1001/jama.289.18.2363
5. Клинические рекомендации «Диагностика и лечение артериальной гипертонии». Рабочая группа по подготовке текста: Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В. Кардиологический вестник. 2015;1:5-30 [Klinicheskie rekomendatsii “Diagnostika i lechenie arterial'noi gipertonii”. Rabochaia gruppa po podgotovke teksta: Chazova IE, Oshchepkova EV, Zhernakova IuV. Kardiologicheskii vestn. 2015;1:5-30 (In Russ.)].
6. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens. 2013;31(7):1281-357. doi: 10.1097/01.hjh. 0000431740.32696.cc.
7. Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, Nair H, Gasevic D, Sridhar D, Campbell H, Chan KY, Sheikh A, Rudan I. Global Health Epidemiology Reference Group (GHERG). Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015;5(2):020415. doi: 10.7189/ jogh.05-020415.
8. Haeusler KG, Herm J, Konieczny M. Impact of chronic inflammatory airway disease on stroke severity and longterm survival after ischemic stroke – a retrospective analysis. BMC Neurol. 2015;15:164. doi: 10.1186/s12883-015-0414-1
9. Hardie JA, Vollmer WM, Buist AS, Bakke P, Morkve O. Respiratory symptoms and obstructive pulmonary disease in a population aged over 70 years. Respir Med. 2005;99:186-95. https://doi.org/10.1016/ j.rmed.2004.06.006
10. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28:523-32. doi:10.1183/09031936.06.00124605
11. Zeng LH, Hu YX, Liu L, Zhang M, Cui H. Impact of beta2-agonists, betablockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease. Clin Interv Aging. 2013;8:1157-65. doi: 10.2147/CIA.S49644. Epub 2013 Sep 10
12. Задионченко В.С., Волкова Н.В., Копалова С.М. Системная и легочная гипертония при хронических неспецифических заболеваниях легких. Русский медицинский журнал. 1996;4(12):28-37 [Zadionchenko VS, Volkova NV, Kopalova SM. System and pulmonary hypertension under the conditions of chronic non-specific pulmonary diseases. Russian Medical Magazine. 1996;4(12):28-37 (In Russ.)].
13. Задионченко В.С., Адашева Т.В., Шилова Е.В. и др. Клинико- функциональные особенности артериальной гипертонии у больных хроническими обструктивными болезнями легких. Русский медицинский журнал. 2003;11(9):535-8 [Zadionchenko VS, Adasheva TV, Shilova EV and others. Clinic and Functional Characteristics of Arterial Hypertension at Patients with Chronic Obstructive Pulmonary Diseases. Russian Medical Magazine. 2003;11(9):535-8 (In Russ.)].
14. Кубышкин В.Ф., Солдатченко С.С., Коновалов В.И. Особенности течения хронических обструктивных заболеваний легких в сочетании с системной артериальной гипертензией. Терапевтический архив. 1985;57(2):114-6 [Kubishkin VF, Soldatchenko SS, Konovalov VI. Characteristics of Clinical Course of Chronic Obstructive Pulmonary Diseases, Combining with System Arterial Hypertension. Therapeutic Archive. 1985;57(2):114-6 (In Russ.)].
15. Dart RA, Gollub S, Lazar J, et al. Treatment of systemic hypertension in patients with pulmonary disease. Chest. 2003;123:222-43.
16. Antonelli Incalzi R, Fuso L, De Rosa M, et al. Comorbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 1997;10:2794-800.
17. Rabahi MF, Pereira SA, Silva Júnior JL, de Rezende AP, Castro da Costa A, de Sousa Corrêa K, et al. Prevalence of chronic obstructive pulmonary disease among patients with systemic arterial hypertension without respiratory symptoms. Int J Chron Obstruct Pulmon Dis. 2015;10:1525-9. doi: 10.2147/COPD.S85588
18. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532-55. doi:10.1164/rccm.200703-456SO
19. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-82. doi:10.1164/rccm.201701-0218PP
20. Nicola Di Daniele. Therapeutic approaches of uncomplicated arterial hypertension in patients with COPD. J Pulmonary Pharmacology & Therapeutics. 2015;35:1-7.
21. Goncalves J, Sanchez R, et al. Cardiovascular comorbidity in patients with chronic obstructive pulmonary disease in the Canary Islands (CCECAN study). J Clin Investig Arteriosclerosis. 2017;29(4):149-56.
22. Чазова И.Е. Артериальная гипертония и хроническая обструктивная болезнь легких. Consilium medicum. 2006;8(5) [Chazova IE. Arterial Hypertension and Chronic Obstructive Pulmonary Disease. Consilium medicum. 2006;8(5) (In Russ.)].
23. Чазова И.Е., Чучалин А.Г., Зыков К.А., Ратова Л.Г. Диагностика и лечение пациентов с артериальной гипертонией и хронической обструктивной болезнью легких (Editorial Российского медицинского общества по артериальной гипертонии и Российского респираторного общества). Системные гипертензии. 2013;1:5-34 [Chazova IE, Chuchalin AG, Zykov KA, Ratova LG. Diagnostics and treatment of patients with an arterial hypertonia and a chronic obstructive pulmonary disease (References of the Russian medical society on an arterial hypertonia and the Russian respiratory society). Systemic Hypertensions. 2013;1:5-34 (In Russ.)].
24. Ощепкова Е.В., Лазарева Н.В., Чазова И.Е. Оценка качества обследования больных артериальной гипертонией в первичном звене здравоохранения (по данным российского Регистра артериальной гипертонии). Системные гипертензии. 2017;14(2):29-34 [Oshchepkova EV, Lazareva NV, Chazova IE. Quality assessment of examination of patients with arterial hypertension in primary health care (according to the Russian arterial hypertension register data). Systemic Hypertension. 2017;14(2):29-34 (In Russ.)]. https://doi.org/10.26442/
25. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonarydisease as an independent risk factor for cardiovascular morbidity. Int J Chronic Obstr Pulmon Dis. 2009;4:337-49.
26. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65:956-62. doi: 10.1136/thx.2009.128082
27. de Lucas-Ramos P, Izquierdo-Alonso JL, Rodriguez-GonzalezMoro JM, Frances JF, Lozano PV, Bellón-Cano JM, CONSISTE study group. Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case-control study (CONSISTE study). Int J Chronic Obstr Pulmon Dis. 2012;7:679-86. doi:10.2147/COPD.S36222
28. Dal Negro RW, Bonadiman L, Turco P. Prevalence of different comorbidities in COPD patients by gender and GOLD stage. Multidiscip Respir Med. 2015;10:24. doi: 10.1186/s40248-015-0023-2
29. Lunde H, Hedner T, Samuelsson O et al. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ. 1994;308:18-21.
30. Benz J, Oshrain C, Henry D, et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidenceof cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol. 1997;37:101-7.
31. Barnes PJ. Clinical studies with calcium antagonists in asthma. Br J Clin Pharmacol. 1985;20(Suppl. 2):289-98.
32. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Claus F. Vogelmeier, Gerard J. Criner Arch Bronconeumol. 2017;53(3):128-49. www.archbronconeumol.org. doi: 10.1016/j.arbres.2017.02.001
33. Sato N, Kajimoto K, et al. Acute demopensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: Rationale, desing, and preliminary data. Am Heart J. 2010;159:949-56. doi:10.1016/j.ahj.2010.03.019
34. Adams Jr KF, Fonarow CC, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209-16. doi:10.1016/j.ahj.2004.08.005
35. Abraham WT, Fonarow GC, et al. Predictor of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol. 2008;52:347-56.
36. Jonsson Asa, Edner Magnus, Alehagen Urban, et al. Heart failure register: a valuable tool for improving the management of patients with heart failure. Eur J Heart Fail. 2010;12:25-31.
37. Ruiz-Laiglesia FJ, Sanchez-Marteles M, Perez-Calvo JI, et al. Comorbidity in heart failure. Results of the Spanish RICA Register. QJM. 2014;107:989-94.
38. Lauthavorn P, Hengrussamee K. Thai acute decompensated heart failure registry (Thai ADHERE). J CVD Prevention and Control. 2010;5:89-95. doi:10.1016/j.cvdpc.2010.06.001
39. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;19:CD003566. doi:10.1002/14651858.CD003566.pub2
40. Mario Malerba, Paolo Montuschi, et al. Role of beta-blockers in patients with COPD: current perspective. Drug Discovery Today Volume. 2015;20(1):129-35.
41. Dart R, Gollub S, Lazar J, et al. Treatment of systemic hypertension in patients with pulmonary disease. Chest. 2003;123:222-43.
42. ONTARGET Investigators, Yusuf S, Teo K, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59.
43. Heart disease and Stroke statistics – 2016 update: a report from the American Heart Association. Circulation. 2016;133.
2. Chazova IE, Oshchepkova EV. Itogi realizatsii Federal'noi tselevoi programmy po profilaktike i lecheniiu arterial'noi gipertenzii v Rossii v 2002–2012 gg. Vestn. Rossiiskoi Akademii meditsinskikh nauk. 2013;2:4-11 (In Russ.)
3. Heart disease and Stroke statistics – 2016 update: a report from the American Heart Association. Circulation. 2016;133.
4. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA. 2003;289:2363-9. doi:10.1001/jama.289.18.2363
5. Klinicheskie rekomendatsii “Diagnostika i lechenie arterial'noi gipertonii”. Rabochaia gruppa po podgotovke teksta: Chazova IE, Oshchepkova EV, Zhernakova IuV. Kardiologicheskii vestn. 2015;1:5-30 (In Russ.)
6. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens. 2013;31(7):1281-357. doi: 10.1097/01.hjh. 0000431740.32696.cc.
7. Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, Nair H, Gasevic D, Sridhar D, Campbell H, Chan KY, Sheikh A, Rudan I. Global Health Epidemiology Reference Group (GHERG). Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015;5(2):020415. doi: 10.7189/ jogh.05-020415.
8. Haeusler KG, Herm J, Konieczny M. Impact of chronic inflammatory airway disease on stroke severity and longterm survival after ischemic stroke – a retrospective analysis. BMC Neurol. 2015;15:164. doi: 10.1186/s12883-015-0414-1
9. Hardie JA, Vollmer WM, Buist AS, Bakke P, Morkve O. Respiratory symptoms and obstructive pulmonary disease in a population aged over 70 years. Respir Med. 2005;99:186-95. https://doi.org/10.1016/ j.rmed.2004.06.006
10. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28:523-32. doi:10.1183/09031936.06.00124605
11. Zeng LH, Hu YX, Liu L, Zhang M, Cui H. Impact of beta2-agonists, betablockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease. Clin Interv Aging. 2013;8:1157-65. doi: 10.2147/CIA.S49644. Epub 2013 Sep 10
12. Zadionchenko VS, Volkova NV, Kopalova SM. System and pulmonary hypertension under the conditions of chronic non-specific pulmonary diseases. Russian Medical Magazine. 1996;4(12):28-37 (In Russ.)
13. Zadionchenko VS, Adasheva TV, Shilova EV and others. Clinic and Functional Characteristics of Arterial Hypertension at Patients with Chronic Obstructive Pulmonary Diseases. Russian Medical Magazine. 2003;11(9):535-8 (In Russ.)
14. Kubishkin VF, Soldatchenko SS, Konovalov VI. Characteristics of Clinical Course of Chronic Obstructive Pulmonary Diseases, Combining with System Arterial Hypertension. Therapeutic Archive. 1985;57(2):114-6 (In Russ.)
15. Dart RA, Gollub S, Lazar J, et al. Treatment of systemic hypertension in patients with pulmonary disease. Chest. 2003;123:222-43.
16. Antonelli Incalzi R, Fuso L, De Rosa M, et al. Comorbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 1997;10:2794-800.
17. Rabahi MF, Pereira SA, Silva Júnior JL, de Rezende AP, Castro da Costa A, de Sousa Corrêa K, et al. Prevalence of chronic obstructive pulmonary disease among patients with systemic arterial hypertension without respiratory symptoms. Int J Chron Obstruct Pulmon Dis. 2015;10:1525-9. doi: 10.2147/COPD.S85588
18. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532-55. doi:10.1164/rccm.200703-456SO
19. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-82. doi:10.1164/rccm.201701-0218PP
20. Nicola Di Daniele. Therapeutic approaches of uncomplicated arterial hypertension in patients with COPD. J Pulmonary Pharmacology & Therapeutics. 2015;35:1-7.
21. Goncalves J, Sanchez R, et al. Cardiovascular comorbidity in patients with chronic obstructive pulmonary disease in the Canary Islands (CCECAN study). J Clin Investig Arteriosclerosis. 2017;29(4):149-56.
22. Чазова И.Е. Артериальная гипертония и хроническая обструктивная болезнь легких. Consilium medicum. 2006;8(5) [Chazova IE. Arterial Hypertension and Chronic Obstructive Pulmonary Disease. Consilium medicum. 2006;8(5) (In Russ.)].
23. Chazova IE, Chuchalin AG, Zykov KA, Ratova LG. Diagnostics and treatment of patients with an arterial hypertonia and a chronic obstructive pulmonary disease (References of the Russian medical society on an arterial hypertonia and the Russian respiratory society). Systemic Hypertensions. 2013;1:5-34 (In Russ.)
24. Oshchepkova EV, Lazareva NV, Chazova IE. Quality assessment of examination of patients with arterial hypertension in primary health care (according to the Russian arterial hypertension register data). Systemic Hypertension. 2017;14(2):29-34 (In Russ.)
https://doi.org/10.26442/
25. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonarydisease as an independent risk factor for cardiovascular morbidity. Int J Chronic Obstr Pulmon Dis. 2009;4:337-49.
26. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65:956-62. doi: 10.1136/thx.2009.128082
27. de Lucas-Ramos P, Izquierdo-Alonso JL, Rodriguez-GonzalezMoro JM, Frances JF, Lozano PV, Bellón-Cano JM, CONSISTE study group. Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case-control study (CONSISTE study). Int J Chronic Obstr Pulmon Dis. 2012;7:679-86. doi:10.2147/COPD.S36222
28. Dal Negro RW, Bonadiman L, Turco P. Prevalence of different comorbidities in COPD patients by gender and GOLD stage. Multidiscip Respir Med. 2015;10:24. doi: 10.1186/s40248-015-0023-2
29. Lunde H, Hedner T, Samuelsson O et al. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ. 1994;308:18-21.
30. Benz J, Oshrain C, Henry D, et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidenceof cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol. 1997;37:101-7.
31. Barnes PJ. Clinical studies with calcium antagonists in asthma. Br J Clin Pharmacol. 1985;20(Suppl. 2):289-98.
32. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Claus F. Vogelmeier, Gerard J. Criner Arch Bronconeumol. 2017;53(3):128-49. www.archbronconeumol.org. doi: 10.1016/j.arbres.2017.02.001
33. Sato N, Kajimoto K, et al. Acute demopensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: Rationale, desing, and preliminary data. Am Heart J. 2010;159:949-56. doi:10.1016/j.ahj.2010.03.019
34. Adams Jr KF, Fonarow CC, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209-16. doi:10.1016/j.ahj.2004.08.005
35. Abraham WT, Fonarow GC, et al. Predictor of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol. 2008;52:347-56.
36. Jonsson Asa, Edner Magnus, Alehagen Urban, et al. Heart failure register: a valuable tool for improving the management of patients with heart failure. Eur J Heart Fail. 2010;12:25-31.
37. Ruiz-Laiglesia FJ, Sanchez-Marteles M, Perez-Calvo JI, et al. Comorbidity in heart failure. Results of the Spanish RICA Register. QJM. 2014;107:989-94.
38. Lauthavorn P, Hengrussamee K. Thai acute decompensated heart failure registry (Thai ADHERE). J CVD Prevention and Control. 2010;5:89-95. doi:10.1016/j.cvdpc.2010.06.001
39. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;19:CD003566. doi:10.1002/14651858.CD003566.pub2
40. Mario Malerba, Paolo Montuschi, et al. Role of beta-blockers in patients with COPD: current perspective. Drug Discovery Today Volume. 2015;20(1):129-35.
41. Dart R, Gollub S, Lazar J, et al. Treatment of systemic hypertension in patients with pulmonary disease. Chest. 2003;123:222-43.
42. ONTARGET Investigators, Yusuf S, Teo K, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59.
43. Heart disease and Stroke statistics – 2016 update: a report from the American Heart Association. Circulation. 2016;133.
2. Чазова И.Е., Ощепкова Е.В. Итоги реализации Федеральной целевой программы по профилактике и лечению артериальной гипертензии в России в 2002–2012 гг. Вестник Российской академии медицинских наук. 2013;2:4-11 [Chazova IE, Oshchepkova EV. Itogi realizatsii Federal'noi tselevoi programmy po profilaktike i lecheniiu arterial'noi gipertenzii v Rossii v 2002–2012 gg. Vestn. Rossiiskoi Akademii meditsinskikh nauk. 2013;2:4-11 (In Russ.)].
3. Heart disease and Stroke statistics – 2016 update: a report from the American Heart Association. Circulation. 2016;133.
4. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA. 2003;289:2363-9. doi:10.1001/jama.289.18.2363
5. Клинические рекомендации «Диагностика и лечение артериальной гипертонии». Рабочая группа по подготовке текста: Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В. Кардиологический вестник. 2015;1:5-30 [Klinicheskie rekomendatsii “Diagnostika i lechenie arterial'noi gipertonii”. Rabochaia gruppa po podgotovke teksta: Chazova IE, Oshchepkova EV, Zhernakova IuV. Kardiologicheskii vestn. 2015;1:5-30 (In Russ.)].
6. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens. 2013;31(7):1281-357. doi: 10.1097/01.hjh. 0000431740.32696.cc.
7. Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, Nair H, Gasevic D, Sridhar D, Campbell H, Chan KY, Sheikh A, Rudan I. Global Health Epidemiology Reference Group (GHERG). Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015;5(2):020415. doi: 10.7189/ jogh.05-020415.
8. Haeusler KG, Herm J, Konieczny M. Impact of chronic inflammatory airway disease on stroke severity and longterm survival after ischemic stroke – a retrospective analysis. BMC Neurol. 2015;15:164. doi: 10.1186/s12883-015-0414-1
9. Hardie JA, Vollmer WM, Buist AS, Bakke P, Morkve O. Respiratory symptoms and obstructive pulmonary disease in a population aged over 70 years. Respir Med. 2005;99:186-95. https://doi.org/10.1016/ j.rmed.2004.06.006
10. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28:523-32. doi:10.1183/09031936.06.00124605
11. Zeng LH, Hu YX, Liu L, Zhang M, Cui H. Impact of beta2-agonists, betablockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease. Clin Interv Aging. 2013;8:1157-65. doi: 10.2147/CIA.S49644. Epub 2013 Sep 10
12. Задионченко В.С., Волкова Н.В., Копалова С.М. Системная и легочная гипертония при хронических неспецифических заболеваниях легких. Русский медицинский журнал. 1996;4(12):28-37 [Zadionchenko VS, Volkova NV, Kopalova SM. System and pulmonary hypertension under the conditions of chronic non-specific pulmonary diseases. Russian Medical Magazine. 1996;4(12):28-37 (In Russ.)].
13. Задионченко В.С., Адашева Т.В., Шилова Е.В. и др. Клинико- функциональные особенности артериальной гипертонии у больных хроническими обструктивными болезнями легких. Русский медицинский журнал. 2003;11(9):535-8 [Zadionchenko VS, Adasheva TV, Shilova EV and others. Clinic and Functional Characteristics of Arterial Hypertension at Patients with Chronic Obstructive Pulmonary Diseases. Russian Medical Magazine. 2003;11(9):535-8 (In Russ.)].
14. Кубышкин В.Ф., Солдатченко С.С., Коновалов В.И. Особенности течения хронических обструктивных заболеваний легких в сочетании с системной артериальной гипертензией. Терапевтический архив. 1985;57(2):114-6 [Kubishkin VF, Soldatchenko SS, Konovalov VI. Characteristics of Clinical Course of Chronic Obstructive Pulmonary Diseases, Combining with System Arterial Hypertension. Therapeutic Archive. 1985;57(2):114-6 (In Russ.)].
15. Dart RA, Gollub S, Lazar J, et al. Treatment of systemic hypertension in patients with pulmonary disease. Chest. 2003;123:222-43.
16. Antonelli Incalzi R, Fuso L, De Rosa M, et al. Comorbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 1997;10:2794-800.
17. Rabahi MF, Pereira SA, Silva Júnior JL, de Rezende AP, Castro da Costa A, de Sousa Corrêa K, et al. Prevalence of chronic obstructive pulmonary disease among patients with systemic arterial hypertension without respiratory symptoms. Int J Chron Obstruct Pulmon Dis. 2015;10:1525-9. doi: 10.2147/COPD.S85588
18. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532-55. doi:10.1164/rccm.200703-456SO
19. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-82. doi:10.1164/rccm.201701-0218PP
20. Nicola Di Daniele. Therapeutic approaches of uncomplicated arterial hypertension in patients with COPD. J Pulmonary Pharmacology & Therapeutics. 2015;35:1-7.
21. Goncalves J, Sanchez R, et al. Cardiovascular comorbidity in patients with chronic obstructive pulmonary disease in the Canary Islands (CCECAN study). J Clin Investig Arteriosclerosis. 2017;29(4):149-56.
22. Чазова И.Е. Артериальная гипертония и хроническая обструктивная болезнь легких. Consilium medicum. 2006;8(5) [Chazova IE. Arterial Hypertension and Chronic Obstructive Pulmonary Disease. Consilium medicum. 2006;8(5) (In Russ.)].
23. Чазова И.Е., Чучалин А.Г., Зыков К.А., Ратова Л.Г. Диагностика и лечение пациентов с артериальной гипертонией и хронической обструктивной болезнью легких (Editorial Российского медицинского общества по артериальной гипертонии и Российского респираторного общества). Системные гипертензии. 2013;1:5-34 [Chazova IE, Chuchalin AG, Zykov KA, Ratova LG. Diagnostics and treatment of patients with an arterial hypertonia and a chronic obstructive pulmonary disease (References of the Russian medical society on an arterial hypertonia and the Russian respiratory society). Systemic Hypertensions. 2013;1:5-34 (In Russ.)].
24. Ощепкова Е.В., Лазарева Н.В., Чазова И.Е. Оценка качества обследования больных артериальной гипертонией в первичном звене здравоохранения (по данным российского Регистра артериальной гипертонии). Системные гипертензии. 2017;14(2):29-34 [Oshchepkova EV, Lazareva NV, Chazova IE. Quality assessment of examination of patients with arterial hypertension in primary health care (according to the Russian arterial hypertension register data). Systemic Hypertension. 2017;14(2):29-34 (In Russ.)]. https://doi.org/10.26442/
25. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonarydisease as an independent risk factor for cardiovascular morbidity. Int J Chronic Obstr Pulmon Dis. 2009;4:337-49.
26. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65:956-62. doi: 10.1136/thx.2009.128082
27. de Lucas-Ramos P, Izquierdo-Alonso JL, Rodriguez-GonzalezMoro JM, Frances JF, Lozano PV, Bellón-Cano JM, CONSISTE study group. Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case-control study (CONSISTE study). Int J Chronic Obstr Pulmon Dis. 2012;7:679-86. doi:10.2147/COPD.S36222
28. Dal Negro RW, Bonadiman L, Turco P. Prevalence of different comorbidities in COPD patients by gender and GOLD stage. Multidiscip Respir Med. 2015;10:24. doi: 10.1186/s40248-015-0023-2
29. Lunde H, Hedner T, Samuelsson O et al. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ. 1994;308:18-21.
30. Benz J, Oshrain C, Henry D, et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidenceof cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol. 1997;37:101-7.
31. Barnes PJ. Clinical studies with calcium antagonists in asthma. Br J Clin Pharmacol. 1985;20(Suppl. 2):289-98.
32. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Claus F. Vogelmeier, Gerard J. Criner Arch Bronconeumol. 2017;53(3):128-49. www.archbronconeumol.org. doi: 10.1016/j.arbres.2017.02.001
33. Sato N, Kajimoto K, et al. Acute demopensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: Rationale, desing, and preliminary data. Am Heart J. 2010;159:949-56. doi:10.1016/j.ahj.2010.03.019
34. Adams Jr KF, Fonarow CC, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209-16. doi:10.1016/j.ahj.2004.08.005
35. Abraham WT, Fonarow GC, et al. Predictor of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol. 2008;52:347-56.
36. Jonsson Asa, Edner Magnus, Alehagen Urban, et al. Heart failure register: a valuable tool for improving the management of patients with heart failure. Eur J Heart Fail. 2010;12:25-31.
37. Ruiz-Laiglesia FJ, Sanchez-Marteles M, Perez-Calvo JI, et al. Comorbidity in heart failure. Results of the Spanish RICA Register. QJM. 2014;107:989-94.
38. Lauthavorn P, Hengrussamee K. Thai acute decompensated heart failure registry (Thai ADHERE). J CVD Prevention and Control. 2010;5:89-95. doi:10.1016/j.cvdpc.2010.06.001
39. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;19:CD003566. doi:10.1002/14651858.CD003566.pub2
40. Mario Malerba, Paolo Montuschi, et al. Role of beta-blockers in patients with COPD: current perspective. Drug Discovery Today Volume. 2015;20(1):129-35.
41. Dart R, Gollub S, Lazar J, et al. Treatment of systemic hypertension in patients with pulmonary disease. Chest. 2003;123:222-43.
42. ONTARGET Investigators, Yusuf S, Teo K, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59.
43. Heart disease and Stroke statistics – 2016 update: a report from the American Heart Association. Circulation. 2016;133.
________________________________________________
2. Chazova IE, Oshchepkova EV. Itogi realizatsii Federal'noi tselevoi programmy po profilaktike i lecheniiu arterial'noi gipertenzii v Rossii v 2002–2012 gg. Vestn. Rossiiskoi Akademii meditsinskikh nauk. 2013;2:4-11 (In Russ.)
3. Heart disease and Stroke statistics – 2016 update: a report from the American Heart Association. Circulation. 2016;133.
4. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA. 2003;289:2363-9. doi:10.1001/jama.289.18.2363
5. Klinicheskie rekomendatsii “Diagnostika i lechenie arterial'noi gipertonii”. Rabochaia gruppa po podgotovke teksta: Chazova IE, Oshchepkova EV, Zhernakova IuV. Kardiologicheskii vestn. 2015;1:5-30 (In Russ.)
6. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens. 2013;31(7):1281-357. doi: 10.1097/01.hjh. 0000431740.32696.cc.
7. Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, Nair H, Gasevic D, Sridhar D, Campbell H, Chan KY, Sheikh A, Rudan I. Global Health Epidemiology Reference Group (GHERG). Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015;5(2):020415. doi: 10.7189/ jogh.05-020415.
8. Haeusler KG, Herm J, Konieczny M. Impact of chronic inflammatory airway disease on stroke severity and longterm survival after ischemic stroke – a retrospective analysis. BMC Neurol. 2015;15:164. doi: 10.1186/s12883-015-0414-1
9. Hardie JA, Vollmer WM, Buist AS, Bakke P, Morkve O. Respiratory symptoms and obstructive pulmonary disease in a population aged over 70 years. Respir Med. 2005;99:186-95. https://doi.org/10.1016/ j.rmed.2004.06.006
10. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28:523-32. doi:10.1183/09031936.06.00124605
11. Zeng LH, Hu YX, Liu L, Zhang M, Cui H. Impact of beta2-agonists, betablockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease. Clin Interv Aging. 2013;8:1157-65. doi: 10.2147/CIA.S49644. Epub 2013 Sep 10
12. Zadionchenko VS, Volkova NV, Kopalova SM. System and pulmonary hypertension under the conditions of chronic non-specific pulmonary diseases. Russian Medical Magazine. 1996;4(12):28-37 (In Russ.)
13. Zadionchenko VS, Adasheva TV, Shilova EV and others. Clinic and Functional Characteristics of Arterial Hypertension at Patients with Chronic Obstructive Pulmonary Diseases. Russian Medical Magazine. 2003;11(9):535-8 (In Russ.)
14. Kubishkin VF, Soldatchenko SS, Konovalov VI. Characteristics of Clinical Course of Chronic Obstructive Pulmonary Diseases, Combining with System Arterial Hypertension. Therapeutic Archive. 1985;57(2):114-6 (In Russ.)
15. Dart RA, Gollub S, Lazar J, et al. Treatment of systemic hypertension in patients with pulmonary disease. Chest. 2003;123:222-43.
16. Antonelli Incalzi R, Fuso L, De Rosa M, et al. Comorbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 1997;10:2794-800.
17. Rabahi MF, Pereira SA, Silva Júnior JL, de Rezende AP, Castro da Costa A, de Sousa Corrêa K, et al. Prevalence of chronic obstructive pulmonary disease among patients with systemic arterial hypertension without respiratory symptoms. Int J Chron Obstruct Pulmon Dis. 2015;10:1525-9. doi: 10.2147/COPD.S85588
18. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532-55. doi:10.1164/rccm.200703-456SO
19. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-82. doi:10.1164/rccm.201701-0218PP
20. Nicola Di Daniele. Therapeutic approaches of uncomplicated arterial hypertension in patients with COPD. J Pulmonary Pharmacology & Therapeutics. 2015;35:1-7.
21. Goncalves J, Sanchez R, et al. Cardiovascular comorbidity in patients with chronic obstructive pulmonary disease in the Canary Islands (CCECAN study). J Clin Investig Arteriosclerosis. 2017;29(4):149-56.
22. Чазова И.Е. Артериальная гипертония и хроническая обструктивная болезнь легких. Consilium medicum. 2006;8(5) [Chazova IE. Arterial Hypertension and Chronic Obstructive Pulmonary Disease. Consilium medicum. 2006;8(5) (In Russ.)].
23. Chazova IE, Chuchalin AG, Zykov KA, Ratova LG. Diagnostics and treatment of patients with an arterial hypertonia and a chronic obstructive pulmonary disease (References of the Russian medical society on an arterial hypertonia and the Russian respiratory society). Systemic Hypertensions. 2013;1:5-34 (In Russ.)
24. Oshchepkova EV, Lazareva NV, Chazova IE. Quality assessment of examination of patients with arterial hypertension in primary health care (according to the Russian arterial hypertension register data). Systemic Hypertension. 2017;14(2):29-34 (In Russ.)
https://doi.org/10.26442/
25. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonarydisease as an independent risk factor for cardiovascular morbidity. Int J Chronic Obstr Pulmon Dis. 2009;4:337-49.
26. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65:956-62. doi: 10.1136/thx.2009.128082
27. de Lucas-Ramos P, Izquierdo-Alonso JL, Rodriguez-GonzalezMoro JM, Frances JF, Lozano PV, Bellón-Cano JM, CONSISTE study group. Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case-control study (CONSISTE study). Int J Chronic Obstr Pulmon Dis. 2012;7:679-86. doi:10.2147/COPD.S36222
28. Dal Negro RW, Bonadiman L, Turco P. Prevalence of different comorbidities in COPD patients by gender and GOLD stage. Multidiscip Respir Med. 2015;10:24. doi: 10.1186/s40248-015-0023-2
29. Lunde H, Hedner T, Samuelsson O et al. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ. 1994;308:18-21.
30. Benz J, Oshrain C, Henry D, et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidenceof cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol. 1997;37:101-7.
31. Barnes PJ. Clinical studies with calcium antagonists in asthma. Br J Clin Pharmacol. 1985;20(Suppl. 2):289-98.
32. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Claus F. Vogelmeier, Gerard J. Criner Arch Bronconeumol. 2017;53(3):128-49. www.archbronconeumol.org. doi: 10.1016/j.arbres.2017.02.001
33. Sato N, Kajimoto K, et al. Acute demopensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: Rationale, desing, and preliminary data. Am Heart J. 2010;159:949-56. doi:10.1016/j.ahj.2010.03.019
34. Adams Jr KF, Fonarow CC, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209-16. doi:10.1016/j.ahj.2004.08.005
35. Abraham WT, Fonarow GC, et al. Predictor of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol. 2008;52:347-56.
36. Jonsson Asa, Edner Magnus, Alehagen Urban, et al. Heart failure register: a valuable tool for improving the management of patients with heart failure. Eur J Heart Fail. 2010;12:25-31.
37. Ruiz-Laiglesia FJ, Sanchez-Marteles M, Perez-Calvo JI, et al. Comorbidity in heart failure. Results of the Spanish RICA Register. QJM. 2014;107:989-94.
38. Lauthavorn P, Hengrussamee K. Thai acute decompensated heart failure registry (Thai ADHERE). J CVD Prevention and Control. 2010;5:89-95. doi:10.1016/j.cvdpc.2010.06.001
39. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;19:CD003566. doi:10.1002/14651858.CD003566.pub2
40. Mario Malerba, Paolo Montuschi, et al. Role of beta-blockers in patients with COPD: current perspective. Drug Discovery Today Volume. 2015;20(1):129-35.
41. Dart R, Gollub S, Lazar J, et al. Treatment of systemic hypertension in patients with pulmonary disease. Chest. 2003;123:222-43.
42. ONTARGET Investigators, Yusuf S, Teo K, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59.
43. Heart disease and Stroke statistics – 2016 update: a report from the American Heart Association. Circulation. 2016;133.
Авторы
И.Е. Чазова, Н.В. Лазарева, Е.В. Ощепкова
ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России, Москва, Россия
National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation, Moscow, Russia
ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России, Москва, Россия
________________________________________________
National Medical Research Center of Cardiology of the Ministry of Health of the Russian Federation, Moscow, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.